Actinic keratosis (AK) is a very common skin disease caused by chronic sun damage, which in 75% of cases arises on chronically sun-exposed areas, such as face, scalp, neck, hands, and forearms. AKs must be considered an early squamous cell carcinoma (SCC)for their probable progression into invasive SCC. For this reason, all AK should be treated, and clinical follow-up is recommended. The aims of treatment are: (i) to clinically eradicate evident and subclinical lesions, (ii) to prevent their evolution into SCC, and (iii) to reduce the number of relapses. Among available treatments, it is possible to distinguish lesiondirected therapies and field-directed therapies. Lesion-directed treatments include: (i) cryotherapy; (ii) laser therapy; (iii) surgery; and (iv) curettage. Whereas, field-directed treatments are: (i) 5-fluorouracil (5-FU); (ii) diclofenac 3% gel; (iii) chemical peeling; (iv) imiquimod; and (v) photodynamic therapy (PDT). Prevention plays an important role in the treatment of AKs, and it is based on the continuous use of sunscreen and protective clothing. This review shows different types of available treatments and describes the characteristics and benefits of each medication, underlining the best choice.
as PR-like eruptions may have peripheral eosinophilia, interface dermatitis and eosinophils on histopathology, with no evidence of HHV-6 and HHV-7 systemic reactivation. 3 Our cases had overlapping features of both PR and PR-like eruptions.COVID-19 has been associated with cases of PR and PRlike eruptions following the acute infection. 6,7 Skin biopsies may demonstrate positivity for the SARS-CoV-2 virus spike protein on endothelial cells and lymphocytes suggesting a direct relationship between SARS-CoV-2 infection and PR. 7 SARS-CoV-2 may also trigger PR by reactivation of HHV-6 or HHV-7. 5 PR eruptions have developed following vaccination for influenza and H1N1 8-10 and may be secondary to reactivation of HHV-6 and HHV-7, which may be detected in skin biopsies via in situ hybridization and immunohistochemistry. 9 Another possible cause for PR in the setting of vaccination is a T-cell-mediated response triggered by molecular mimicry from a viral epitope. 8 Given worldwide vaccination efforts against COVID-19 with mRNA vaccines, it is important for doctors and patients to recognize possible adverse events including PR. Further study is required to confirm the causative link, including direct examination of tissue and serological studies for evidence of HHV-6 and HHV-7 reactivation.
There have been increasing reports of skin manifestations in COVID-19 patients. We conducted a systematic review and included manuscripts describing patients with positive RT-PCR coronavirus testing from nasopharyngeal swabs who also developed cutaneous manifestations. A total of 655 patients were selected, with different types of skin rashes: Erythematous maculopapular (n = 250), vascular (n = 146), vesicular (n = 99), urticarial (n = 98), erythema multiforme/generalized pustular figurate erythema/Stevens-Johnson syndrome (n = 22), ocular/periocular (n = 14), polymorphic pattern (n = 9), generalized pruritus (n = 8), Kawasaki disease (n = 5), atypical erythema nodosum (n = 3), and atypical Sweet syndrome (n = 1). Chilblain-like lesions were more frequent in the younger population and were linked to a milder disease course, while fixed livedo racemosa and retiform purpura appeared in older patients and seemed to predict a more severe prognosis. For vesicular rashes, PCR determined the presence of herpesviruses in the vesicle fluid, which raised the possibility of herpesvirus co-infections. The erythema-multiforme-like pattern, generalized pustular figurate erythema and Stevens-Johnson syndrome were most frequently linked to hydroxychloroquine intake. A positive PCR determination of SARS-COV-2 from conjunctival swabs suggest that eye discharge can also be contagious. These cutaneous manifestations may aid in identifying otherwise asymptomatic COVID-19 carriers in some cases or predict a more severe evolution in others.
Background Epidemiologic data suggest an increased risk of melanoma (MM) and non‐melanoma skin cancer (NMSC) in persons with intense recreational sun‐exposure such as marathon runners or surfers. Up to data little is known about the sun‐exposure habits, sun‐protection behaviours and risk factors for MM and NMSC among sailors. Objective The objective of this prospective, cross‐sectional study was to investigate the sun‐exposure and sun‐protective habits and risk factors for skin cancer among sailors attending the 50° edition of Barcolana, the largest sailing race in of the world, which took place in October 2018 in Trieste, Italy as an integrative component of a public sun‐prevention campaign. Methods The study consisted of 2 parts: (i) a self‐administered questionnaire focusing on sun‐exposure and protective habits and (ii) a free skin examination carried out by volunteer dermatologists. Participation was optional and anonymous, and open to visitors and sailors attending the event. Results Overall, 431 (52.4%) sailors and 391 (47.6%) visitors responded to the questionnaire, while a total of 437 individuals including 189 (43.3%) sailors and 248 (56.6%) visitors participated in the skin examination group. The majority of sailors reported a past history of severe sunburns (20.2%), applied sunscreen never (14.4%) to sometimes (45.7%) or only once daily (59%) on the face (55%) and shoulders (26%). Moreover, 14% of sailors had a personal history of non‐melanoma skin cancer (NMSC). During the dermatological examination, suspicious lesions for skin cancer (including MM and NMSC) were identified in 37% of the sailors. Conclusion Our findings support the need to develop and promote primary and secondary prevention strategies to improve the sun‐exposure and sun‐protective habits among sailors.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.